Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azatadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.79 |
| ▸ | DRD2 | P14416 | 2/20 | 0.79 |
| ▸ | HTR2A | P28223 | 2/20 | 0.79 |
| ▸ | HTR2C | P28335 | 2/20 | 0.79 |
| ▸ | HTR1A | P08908 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | HTR2B | P41595 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | PTAFR | P25105 | 10/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 2/20 | 0.57 |
| ▸ | FNTB | P49356 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azatadine SCHEMBL450676 | 1.00 | HRH1 (0.79) | HRH1CHRM2CHRM1DRD2HTR2A | |
| Azatadine SCHEMBL450674 | 1.00 | HRH1 (0.79) | HRH1CHRM2CHRM1DRD2HTR2A | |
| Azatadine SCHEMBL29746602 | 0.89 | HRH1 (1.00) | HRH1CHRM2CHRM1DRD2HTR2A | |
| Azatadine SCHEMBL3721 | 0.89 | HRH1 (1.00) | HRH1CHRM2CHRM1DRD2HTR2A | |
| Azatadine SCHEMBL29363595 | 0.89 | HRH1 (1.00) | HRH1CHRM2CHRM1DRD2HTR2A | |
| Azatadine SCHEMBL6061443 | 0.88 | HRH1 (0.97) | HRH1CHRM2CHRM1DRD2HTR2A | |
| SCHEMBL9215889 | 0.84 | HRH1 (0.89) | HRH1CHRM2CHRM1DRD2HTR2A | |
| SCHEMBL8877892 | 0.82 | PTAFR (1.00) | HRH1CHRM2CHRM1DRD2HTR2A | |
| Cyproheptadine SCHEMBL5934940 | 0.81 | HRH1 (0.83) | HRH1CHRM2CHRM1DRD2HTR2A | |
| SCHEMBL8879303 | 0.80 | PTAFR (0.74) | HRH1CHRM2CHRM1DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114073690-B | Extraction-preventing pharmaceutical composition containing amino acid and preparation thereof | 江苏长泰药业有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-114073689-B | Extraction-preventing pharmaceutical composition and preparation thereof | 江苏长泰药业有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-114073689-A | Anti-extraction pharmaceutical composition and preparation thereof | 江苏长泰药业有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-114073690-A | Amino acid-containing anti-extraction pharmaceutical composition and preparation thereof | 江苏长泰药业有限公司 | 2022-02-22 | — | — | CN | claimed |
| EP-3565532-A1 | ORAL DISPERSIBLE FILM COMPOSITION | Bonayo Lifesciences Private Limited (IN) | 2019-11-13 | — | — | EP | claimed |
| US-20190336453-A1 | ORAL DISPERSIBLE FILM COMPOSITION | BonAyu Lifesciences Private Limited (IN) | 2019-11-07 | — | — | US | claimed |
| WO-2018127938-A1 | ORAL DISPERSIBLE FILM COMPOSITION | JUBELN LIFESCIENCES PVT. LTD. (IN) | 2018-07-12 | — | — | WO | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-8679535-B2 | Sustained release matrix systems for highly soluble drugs | ENDO PHARMACEUTICALS INC. (US) | 2014-03-25 | — | — | US | claimed |
| CN-101927002-B | Medicament and coating composition | ZHONG SHUGUANG | 2014-03-12 | — | — | CN | claimed |
| US-5614178-A | TRANSDERMAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-03-25 | — | — | US | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0652774-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. | PROCTER & GAMBLE (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |